Tauriga Sciences Inc. (OTCMKTS:TAUG) which is based in New York, has announced that its quarterly revenue for 2nd Fiscal Quarter 2022 (Period: July 1st– September 30th, 2021), has surpassed previous records. Tauriga is a diversified Life Sciences Company whose net quarterly revenue has moved past $125,000, for the very first time. The company’s gross revenue was significantly higher.
The main product inventory was obtained by the company in the first week of August 2021. There was no looking back since then, as customer feedback has been mostly positive. Their client base has also grown consistently. Safe to say, the company is doing quite well.
Tauriga has six active sources of revenue at present: Retail Sales, Ecommerce Sales, Sales from Amazon.com, Tradeshow Sales, International Transactions, Subscription “Recurring” Sales.
Since ecommerce is ruling the roost now, with the pandemic forcing people to flock to digital channels, it isn’t surprising that the ecommerce section is the most profitable. The company’s highest margin ecommerce business segment has accounted for around 65% of the total net quarterly revenue.
The company also realizes the crucial progress when it comes to their ongoing pharmaceutical development efforts. Shareholders will get an additional update as soon as it is feasible.
Market Reaction:
On Friday, TAUG stock fell marginally to $0.0402 with more than 303K shares, compared to its average volume of 622K shares. The stock has moved within a range of $0.0360 – 0.0408 after opening the trade at $0.0405.
